

Rosanna Smart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3146255/publications.pdf>

Version: 2024-02-01

35
papers

1,054
citations

759233

12
h-index

454955

30
g-index

36
all docs

36
docs citations

36
times ranked

1095
citing authors

#	ARTICLE	IF	CITATIONS
1	Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. <i>Addiction</i> , 2017, 112, 2167-2177.	3.3	257
2	Medical Marijuana and Marijuana Legalization. <i>Annual Review of Clinical Psychology</i> , 2017, 13, 397-419.	12.3	201
3	Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: Findings from state policy evaluations. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 644-663.	2.1	180
4	Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States. <i>Addiction</i> , 2021, 116, 6-17.	3.3	56
5	Changes in firearm mortality following the implementation of state laws regulating firearm access and use. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 14906-14910.	7.1	50
6	The state of the science in opioid policy research. <i>Drug and Alcohol Dependence</i> , 2020, 214, 108137.	3.2	26
7	How high: Differences in the developments of cannabis markets in two legalized states. <i>International Journal of Drug Policy</i> , 2020, 75, 102611.	3.3	25
8	Considering Heroin-Assisted Treatment and Supervised Drug Consumption Sites in the United States. , 2018, , .		24
9	Assessment of State and Federal Health Policies for Opioid Use Disorder Treatment During the COVID-19 Pandemic and Beyond. <i>JAMA Health Forum</i> , 2021, 2, e213833.	2.2	21
10	Strengths and weaknesses of existing data sources to support research to address the opioids crisis. <i>Preventive Medicine Reports</i> , 2020, 17, 101015.	1.8	20
11	Individual and Community Factors Associated with Naloxone Co-prescribing Among Long-term Opioid Patients: a Retrospective Analysis. <i>Journal of General Internal Medicine</i> , 2021, 36, 2952-2957.	2.6	19
12	Legal requirements and recommendations to prescribe naloxone. <i>Drug and Alcohol Dependence</i> , 2020, 209, 107896.	3.2	17
13	A difference-in-difference approach to examining the impact of cannabis legalization on disparities in the use of cigarettes and cannabis in the United States, 2004-17. <i>Addiction</i> , 2022, 117, 1768-1777.	3.3	16
14	Who Receives Naloxone from Emergency Medical Services? Characteristics of Calls and Recent Trends. <i>Substance Abuse</i> , 2020, 41, 400-407.	2.3	15
15	Does heroin-assisted treatment reduce crime? A review of randomized-controlled trials. <i>Addiction</i> , 2022, 117, 518-531.	3.3	13
16	Relationships of Cannabis Policy Liberalization With Alcohol Use and Co-Use With Cannabis: A Narrative Review. <i>Alcohol Research: Current Reviews</i> , 2022, 41, 06.	3.6	12
17	An Observational Study of Retail Pharmacy Naloxone Prescriptions: Differences Across Provider Specialties and Patient Populations. <i>Journal of General Internal Medicine</i> , 2020, 35, 1768-1775.	2.6	10
18	Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108569.	3.2	10

#	ARTICLE	IF	CITATIONS
19	Moving beyond the classic difference-in-differences model: a simulation study comparing statistical methods for estimating effectiveness of state-level policies. BMC Medical Research Methodology, 2021, 21, 279.	3.1	10
20	Current U.S. State Cannabis Sales Limits Allow Large Doses for Use or Diversion. American Journal of Preventive Medicine, 2021, 60, 701-705.	3.0	9
21	After the Grand Opening: Assessing Cannabis Supply and Demand in Washington State. , 2019, , .		9
22	Differences in alcohol cognitions, consumption, and consequences among first-time DUI offenders who co-use alcohol and marijuana. Drug and Alcohol Dependence, 2018, 191, 187-194.	3.2	8
23	Evidence on the Effectiveness of Heroin-Assisted Treatment. , 2018, , .		6
24	Effectiveness and implementability of state-level naloxone access policies: Expert consensus from an online modified-Delphi process. International Journal of Drug Policy, 2021, 98, 103383.	3.3	5
25	We Need a Taxonomy of State-Level Opioid Policies. JAMA Health Forum, 2020, 1, e200050.	2.2	5
26	Association of Cannabis Legalization and Decriminalization With Arrest Rates of Youths. JAMA Pediatrics, 2019, 173, 725.	6.2	4
27	Racial Differences in Civic Participation and Charitable Giving: The Confounding Effects of Educational Attainment and Unmeasured Ability. Review of Black Political Economy, 2007, 34, 259-271.	1.1	3
28	Prescribing diamorphine in the United States: Insights from a nationally representative survey. Drug and Alcohol Dependence, 2019, 196, 62-65.	3.2	3
29	Rating the comparative efficacy of state-level cannabis policies on recreational cannabis markets in the United States. International Journal of Drug Policy, 2022, 106, 103744.	3.3	3
30	Methodological considerations for estimating policy effects in the context of co-occurring policies. Health Services and Outcomes Research Methodology, 0, , .	1.8	3
31	Response to Commentaries: new data sources for understanding cannabis markets. Addiction, 2017, 112, 2180-2181.	3.3	2
32	Acknowledging and monitoring the costs of seriously regulating cannabis. Addiction, 2021, 116, 235-236.	3.3	2
33	Expert views on state-level naloxone access laws: a qualitative analysis of an online modified-Delphi process. Harm Reduction Journal, 2022, 19, .	3.2	2
34	Prescribers and Naloxone Pharmacy Claims. Journal of General Internal Medicine, 2020, 35, 2475-2475.	2.6	1
35	Capsule Commentary for Azcarate et al., Medical Reasons for Marijuana Use, Forms of Use, and Patient Perception of Physician Attitudes Among the US Population. Journal of General Internal Medicine, 2020, 35, 2252-2252.	2.6	0